We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Incyte (INCY) Partners With Cellenkos for Myelofibrosis Treatment
Read MoreHide Full Article
Incyte (INCY - Free Report) announced a global development collaboration agreement with privately-held clinical-stage biotech company, Cellenkos, Inc.
The companies have collaborated to investigate the combination of Incyte’s lead drug Jakafi (ruxolitinib) and CK0804, Cellenkos’ cryopreserved CXCR4 enriched, allogeneic, umbilical cord blood-derived T-regulatory cells, in patients with myelofibrosis (MF), which is a rare, chronic blood cancer.
Additionally, Incyte gains an exclusive option to acquire sole rights to develop and commercialize CK0804 and genetically-modified variants of CK0804 in benign and malignant hematology indications.
Per the agreement, both companies intend to initiate a phase Ib single-arm, open-label study evaluating Jakafi in combination with CK0804 in patients with MF. The study will be funded by Incyte and operationalized by Cellenkos.
Incyte also has an option to acquire an exclusive global license to develop and commercialize the program. The company would be responsible for all activities and costs associated with research, development and commercialization of the program, once it exercises the global licensing option. Meanwhile, Cellenkos would be eligible to receive a $20-million licensing fee along with development, regulatory and sales milestones totaling up to $294.5 million for each distinct product under the agreement. It is also entitled to tiered royalties ranging from mid-single digit to low-double digits on approval.
We note that Jakafi, a first-in-class JAK1/JAK2 inhibitor, is already approved by the FDA for the treatment of polycythemia vera (PV) in adults who have had an inadequate response to or are intolerant of hydroxyurea, adults with intermediate or high-risk MF including primary MF, post-polycythemia vera MF and post-essential thrombocythemia MF. It is also approved for the treatment of steroid-refractory acute GVHD in adult and pediatric patients 12 years and older.
The drug is marketed by Incyte in the United States and by Novartis (NVS - Free Report) , as Jakavi, outside the country.
Shares of the company have lost 0.5% in the year against the industry’s 8% growth.
The company’s efforts to diversify its revenue base are encouraging as well and the label expansion of Jakafi in additional indications will further boost sales. Moreover, the recent approval of Pemazyre, Monjuvi in collaboration with MorphoSys (MOR - Free Report) and Tabrecta (with Novartis) will bring additional sales and diversify its revenue base.
Halozyme’s earnings estimates have grown 22 cents for 2020 and 28 cents for 2021 in the past 60 days.
Legal Marijuana: An Investor’s Dream
Imagine getting in early on a young industry primed to skyrocket from $17.7 billion in 2019 to an expected $73.6 billion by 2027.
Although marijuana stocks did better as the pandemic took hold than the market as a whole, they’ve been pushed down. This is exactly the right time to get in on selected strong companies at a fraction of their value before COVID struck. Zacks’ Special Report, Marijuana Moneymakers, reveals 10 exciting tickers for urgent consideration.
Image: Bigstock
Incyte (INCY) Partners With Cellenkos for Myelofibrosis Treatment
Incyte (INCY - Free Report) announced a global development collaboration agreement with privately-held clinical-stage biotech company, Cellenkos, Inc.
The companies have collaborated to investigate the combination of Incyte’s lead drug Jakafi (ruxolitinib) and CK0804, Cellenkos’ cryopreserved CXCR4 enriched, allogeneic, umbilical cord blood-derived T-regulatory cells, in patients with myelofibrosis (MF), which is a rare, chronic blood cancer.
Additionally, Incyte gains an exclusive option to acquire sole rights to develop and commercialize CK0804 and genetically-modified variants of CK0804 in benign and malignant hematology indications.
Per the agreement, both companies intend to initiate a phase Ib single-arm, open-label study evaluating Jakafi in combination with CK0804 in patients with MF. The study will be funded by Incyte and operationalized by Cellenkos.
Incyte also has an option to acquire an exclusive global license to develop and commercialize the program. The company would be responsible for all activities and costs associated with research, development and commercialization of the program, once it exercises the global licensing option.
Meanwhile, Cellenkos would be eligible to receive a $20-million licensing fee along with development, regulatory and sales milestones totaling up to $294.5 million for each distinct product under the agreement. It is also entitled to tiered royalties ranging from mid-single digit to low-double digits on approval.
We note that Jakafi, a first-in-class JAK1/JAK2 inhibitor, is already approved by the FDA for the treatment of polycythemia vera (PV) in adults who have had an inadequate response to or are intolerant of hydroxyurea, adults with intermediate or high-risk MF including primary MF, post-polycythemia vera MF and post-essential thrombocythemia MF. It is also approved for the treatment of steroid-refractory acute GVHD in adult and pediatric patients 12 years and older.
The drug is marketed by Incyte in the United States and by Novartis (NVS - Free Report) , as Jakavi, outside the country.
Shares of the company have lost 0.5% in the year against the industry’s 8% growth.
The company’s efforts to diversify its revenue base are encouraging as well and the label expansion of Jakafi in additional indications will further boost sales. Moreover, the recent approval of Pemazyre, Monjuvi in collaboration with MorphoSys (MOR - Free Report) and Tabrecta (with Novartis) will bring additional sales and diversify its revenue base.
Incyte currently carries a Zacks Rank #4 (Sell). A better-ranked stock in the healthcare sector is Halozyme Therapeutics, Inc. (HALO - Free Report) , which carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Halozyme’s earnings estimates have grown 22 cents for 2020 and 28 cents for 2021 in the past 60 days.
Legal Marijuana: An Investor’s Dream
Imagine getting in early on a young industry primed to skyrocket from $17.7 billion in 2019 to an expected $73.6 billion by 2027.
Although marijuana stocks did better as the pandemic took hold than the market as a whole, they’ve been pushed down. This is exactly the right time to get in on selected strong companies at a fraction of their value before COVID struck. Zacks’ Special Report, Marijuana Moneymakers, reveals 10 exciting tickers for urgent consideration.
Download Marijuana Moneymakers FREE >>